Midazolam Accord

Midazolam, the active ingredient in Midazolam Accord, is a benzodiazepine presented as a solution for injection for intramuscular and intravenous use. It provides sedation and anxiolysis in various clinical settings, including pre‑operative medication, procedural sedation, induction of anesthesia, and status epilepticus.

GNH USA supplies Midazolam Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Midazolam is a benzodiazepine that acts on the central nervous system to produce sedation and anxiolysis.

Sedation: provides controlled sedation for diagnostic or therapeutic procedures. Anxiolysis: reduces anxiety before surgery or invasive procedures. Pre‑operative medication: prepares patients for anesthesia by calming and reducing reflexes. Induction of anesthesia: facilitates rapid onset of general anesthesia. Procedural sedation: enables safe sedation during minor surgeries or endoscopic procedures. Status epilepticus: used as an adjunct to control refractory seizures.

Midazolam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Dizziness - Fatigue - Nausea

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Paradoxical agitation - Anaphylaxis - Cardiac arrhythmia - Loss of consciousness

Prior to administration, clinicians should consider several safety measures.

Assess respiratory function: monitor breathing and oxygen saturation during and after administration. Evaluate hepatic function: dose may need adjustment in severe liver impairment. Use caution in the elderly: increased sensitivity to sedative effects. Avoid concomitant CNS depressants: risk of additive sedation and respiratory depression. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Midazolam interacts with several drug classes that may alter its safety or efficacy.

Major Interactions (Avoid): - Opioids: additive respiratory depression. - Barbiturates: profound CNS depression. - General anesthetics: enhanced sedative effect. - Alcohol: increased sedation and risk of respiratory compromise.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin): may reduce efficacy. - CYP3A4 inhibitors (e.g., ketoconazole): increase plasma levels. - CYP3A4 inducers (e.g., rifampin): decrease plasma levels. - Antidepressants (e.g., SSRIs): may increase sedation.